Lower-Dose DMPA

Product Overview

Description: A single subcutaneous injection of medroxyprogesterone acetate injectable suspension, (dose between 45mg - 105mg), currently approved for IM use, every 3 months

Updated date: May 30, 2018

Vertical Tabs

Status

Began discovery in: 2013

Status Details:
  • Currently in recruitment and follow up of Phase I study.

Download Product Report